Clinical trials: Chronic Lymphoblastic Leukemia
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
This trial will evaluate the safety and efficacy of a reduced intensity allogeneic HSCT from partially HLA-mismatched first-degree relatives utilizing PBSC as the stem cell source.
- Conditions
- Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
- Trial name
- NCT02581007
- Testing
- Fludarabine, Melphalan, Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northside Hospital, Inc.
Chronic Lymphocytic Leukemia
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.
- Trial name
- NCT02477696
- Testing
- Acalabrutinib, Ibrutinib
- Where
- 130 sites in United States, Australia and 13 more
- Volunteers
- 533 people
- Sponsor
- Acerta Pharma BV
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
This randomized phase II trial studies how well giving rasburicase together with allopurinol works in treating patients with hematologic malignancies. Rasburicase may reduce the level of uric acid in the blood.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT01564277
- Testing
- rasburicase, allopurinol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Myelodysplastic Syndrome, Myelofibrosis
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
The purpose of this study is to assess the bioequivalence of subcutaneous Vidaza® and subcutaneous Luitpold Azacitidine pharmacokinetics and to assess the comparative safety of subcutaneous Vidaza® versus subcutaneous Luitpold…
- Conditions
- Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT01290302
- Testing
- Luitpold Azacitidine, Vidaza®
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- American Regent, Inc.
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Reduced Intensity Double Umbilical Cord Blood Transplantation
This trial will use two cord blood units for transplantation using a reduced intensity regimen rather than using intense doses of chemotherapy and radiation therapy.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01408563
- Testing
- Fludarabine, Melphalan, Total Body Radiation
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
Leukemia
Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
The goal of this clinical research study is to learn if PCI-32765 (Ibrutinib) combined with rituximab can help to control CLL and SLL. The safety of this combination will also be studied.
- Trial name
- NCT01520519
- Testing
- Rituximab, PCI-32765
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
RATIONALE: Chemotherapy, such as busulfan, melphalan, and thiotepa, may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow.
- Trial name
- NCT00238433
- Testing
- filgrastim, busulfan, melphalan
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- OHSU Knight Cancer Institute
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
A Phase I/II Study of Intratumoral Injection of SD-101
This phase 1-2 trial studies the side effects and best dose of ipilimumab in combination with toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with recurrent low-grade B-cell lymphoma.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT02254772
- Testing
- Ipilimumab, SD-101, Radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Robert Lowsky
Acute Leukemia, Chronic Myelogenous Leukemia
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Acute Graft-versus-Host-Disease (GVHD) is an important cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT).
- Conditions
- Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Chronic Lymphocytic Leukemia
- Trial name
- NCT02208037
- Testing
- Tacrolimus (ARM with Methotrexate), Tacrolimus (ARM with MMF and Cyclophosphamide), Methotrexate (ARM with Maraviroc)
- Where
- 30 sites in United States
- Volunteers
- 279 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hematological Malignancies
Pasireotide in Prevention of GI Toxicity
The purpose of this study is to evaluate if the drug, Pasireotide, is safe and effective in reducing the gastrointestinal side effects of the drugs received to prepare for allogeneic stem cell transplant.
- Trial name
- NCT02215070
- Testing
- Pasireotide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Anthony Sung, MD
Chronic Lymphocytic Leukemia, 17p Deletion
A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion
This was an open-label, multicenter, global study to determine the efficacy of ABT-199 (Venetoclax) monotherapy in participants with relapsed/refractory (R/R) or previously untreated chronic lymphocytic leukemia (CLL) harboring…
- Conditions
- Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
- Trial name
- NCT01889186
- Testing
- ABT-199 (Main Cohort), ABT-199 (Safety Expansion Cohort)
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 158 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
- Trial name
- NCT02717611
- Testing
- ACP-196 (acalabrutinib)
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Acerta Pharma BV
Graft Versus Host Disease, Leukemia
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell and donor natural killer cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00450983
- Testing
- muromonab-CD3, natural killer cell therapy, fludarabine phosphate
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
This is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT03674411
- Testing
- Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
This study will evaluate combining stem cells from the patient's matched sibling donor (a standard CD34-selected transplant) with a second infusion of white blood cells called "CD8 memory T-cells" from their sibling donor.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Acute Leukemia
- Trial name
- NCT04151706
- Testing
- CD8+ Memory T Cell Infusion, Thiotepa, Fludarabine
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Robert Lowsky
Lymphocytic Leukemia, Chronic
A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
This single arm study will assess the safety and effect on response rate of a combination of rituximab and chlorambucil in previously untreated participants with B-cell chronic lymphocytic leukemia.
- Trial name
- NCT00532129
- Testing
- Rituximab, Chlorambucil
- Where
- 12 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
This multi-center, randomized study compared the efficacy and safety of MabThera (rituximab) in combination with either fludarabine and cyclophosphamide or with chlorambucil in participants with previously untreated B-cell…
- Trial name
- NCT01283386
- Testing
- Chlorambucil, Cyclophosphamide, Fludarabine
- Where
- 8 sites in Russia
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.
This study aimed to assess the optimal duration of nilotinib 300 mg twice daily (BID) consolidation treatment in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), in order that patients remained…
- Trial name
- ENESTPath (NCT01743989)
- Testing
- Nilotinib
- Where
- 208 sites in Austria, Belgium and 19 more
- Volunteers
- 620 people
- Sponsor
- Novartis Pharmaceuticals
Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Phase II trial to study the effectiveness of combining rituximab and rasburicase with combination chemotherapy in treating young patients who have newly diagnosed advanced B-cell leukemia or lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Stage I Childhood Large Cell Lymphoma
- Trial name
- NCT00057811
- Testing
- doxorubicin hydrochloride, cyclophosphamide, methotrexate
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Children's Oncology Group
Multiple Myeloma, Leukemia
Cellular Therapy With Cord Blood Cells
The goal of this clinical research study is to learn if giving umbilical cord blood along with standard stem cells after high-dose chemotherapy will improve the response to a stem cell transplant.
- Conditions
- Multiple Myeloma, Leukemia, Lymphoma
- Trial name
- NCT00427557
- Testing
- Fludarabine, Melphalan, Umbilical Cord Blood
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center